drug

MEM 3454

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Memory Pharmaceuticals
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
NCT00725855Phase 2Unknown
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
NCT00604760Phase 2Unknown

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Memory Pharmaceuticals
company
trial
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
PHASE2
trial
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Cognitive Impairment Associated With Schizophrenia
indication
Schizophrenia
indication